Oculis (NASDAQ:OCS) Trading 3.8% Higher – What’s Next?

Oculis Holding AG (NASDAQ:OCS)’s share price traded up 3.8% on Tuesday . The stock traded as high as $15.17 and last traded at $15.17. 5,473 shares changed hands during trading, a decline of 85% from the average session volume of 36,819 shares. The stock had previously closed at $14.62.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Oculis in a research note on Monday, November 11th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Oculis currently has an average rating of “Buy” and an average price target of $29.20.

Oculis Trading Down 0.7 %

The stock’s 50-day moving average price is $14.47 and its 200-day moving average price is $12.74. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. The business had revenue of $0.27 million during the quarter, compared to analyst estimates of $0.28 million. Research analysts predict that Oculis Holding AG will post -2.09 EPS for the current year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.